ArticleCureus2026
Prenatal Diagnosis of Immune-Mediated Fetal Complete Heart Block Revealing Maternal Systemic Lupus Erythematosus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated congenital heart block (CHB) is a rare but severe manifestation of neonatal lupus, resulting from transplacental transfer of maternal anti-SSA/Ro and anti-SSB/La antibodies. It is associated with significant fetal and neonatal morbidity and mortality and may reveal previously undiagnosed maternal autoimmune disease. We report the case of a 34-year-old multigravida woman with no known systemic disease, referred at 29 weeks of gestation for suspected fetal arrhythmia. Fetal echocardiography revealed complete atrioventricular block associated with myocardial hypertrophy and pericardial effusion. Maternal immunologic screening demonstrated high titers of anti-SSA/Ro and anti-SSB/La antibodies, leading to the diagnosis of systemic lupus erythematosus. Despite multidisciplinary management and antenatal planning, the neonate developed severe postnatal bradyarrhythmia and heart failure, resulting in death on day 4 of life. This case highlights the pathogenic mechanisms, diagnostic challenges, and therapeutic strategies of immune-mediated CHB. Early detection through serial fetal echocardiography and maternal antibody screening is essential, as established complete CHB remains largely irreversible. Preventive therapy with hydroxychloroquine has emerged as the most effective strategy to reduce recurrence risk by more than 50% in subsequent pregnancies, based on recent prospective trials. Immune-mediated CHB may be the first manifestation of maternal autoimmune disease. Systematic immunologic screening, close fetal surveillance, and preventive treatment with hydroxychloroquine are crucial to optimize maternal and neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.